ImmunityBio (IBRX) Liabilities and Shareholders Equity (2014 - 2026)

ImmunityBio (IBRX) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $646.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 112.88% year-over-year to $646.6 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 38.38% YoY), while the FY2025 annual figure was $501.9 million, up 31.07% from the prior year.
• Liabilities and Shareholders Equity climbed to $646.6 million in Q1 2026 per IBRX's latest filing, from $501.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $646.6 million in Q1 2026 and bottomed at $291.2 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $409.4 million across 5 years, with a median of $389.6 million in 2022.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slipped 24.19% — and 2026, when it surged 112.88%.
• ImmunityBio's Liabilities and Shareholders Equity stood at $362.4 million in 2022, then soared by 39.21% to $504.5 million in 2023, then slipped by 24.09% to $382.9 million in 2024, then soared by 31.07% to $501.9 million in 2025, then grew by 28.84% to $646.6 million in 2026.
• Business Quant data shows IBRX's Liabilities and Shareholders Equity at $646.6 million in Q1 2026, $501.9 million in Q4 2025, and $519.0 million in Q3 2025.